Coronavirus: Serum Institute CEO delighted with Covishield vaccine efficacy
Synopsis
"Delighted to hear that, Covishield, soon to be widely available Covid-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another," said Poonawalla.
New Delhi: Serum Institute of India (SII), CEO, Adar Poonawalla on Monday said that he is delighted to hear that Covidshield, soon to be widely available Covid-19 vaccine, will offer protection up to 90% in one dosage regime and 62% in another.
"Delighted to hear that, Covishield, soon to be widely available Covid-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another," said Poonawalla.
The Oxford-AstraZeneca vaccine is being made in partnership with Serum Institute.
With an efficacy of around 90%, positive results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil the vaccine has proved to be highly effective in preventing Covid-19 said AstraZeneca on Monday.
One dosing regimen shows the vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least a month apart. Second dosing regimen shows 62% efficacy when given two full doses at least a month apart. Combined analysis has an average efficacy of 70%, AstraZeneca said in a statement.